Verrica Parmaceuticals【VRCA】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.80

買値

0.78

売値

0.81

出来高

283,053

0.8495 日の範囲 0.92

0.7043 52 週間の範囲 11.41

時価総額

36.481M

前日終値

0.89

始値

0.89

時刻

1376

0.8

(formt)

最終取引時間

財務取引量

US$ 252,653

VWAP

0.892601

平均取引量 (3 か月)

950,469

発行済株式数

45,600,795

配当利回り

PER

-0.61

1 株当たり利益 (EPS)

-1.47

歳入

5.12M

純利益

-67M

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, ... Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.verrica.com

本社

Wilmington, Delaware, USA

設立

Verrica Parmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker VRCA. The last closing price for Verrica Parmaceuticals was US$0.89. Over the last year, Verrica Parmaceuticals shares have traded in a share price range of US$ 0.7043 to US$ 11.41.

Verrica Parmaceuticals currently has 45,600,795 shares in issue. The market capitalisation of Verrica Parmaceuticals is US$40.58 million. Verrica Parmaceuticals has a price to earnings ratio (PE ratio) of -0.61.

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.11	-12.0879120879	0.91	0.94	0.71	370383	0.86646491	CS
4	-0.79	-49.6855345912	1.59	1.7382	0.7043	769208	0.96308564	CS
12	-1.68	-67.7419354839	2.48	2.52	0.7043	950469	1.5284916	CS
26	-7.84	-90.7407407407	8.64	9.395	0.7043	676770	2.64786932	CS
52	-2.7	-77.1428571429	3.5	11.41	0.7043	664826	4.35252803	CS
156	-11.275	-93.3747412008	12.075	12.075	0.7043	366395	4.45744156	CS
260	-13.47	-94.3938332165	14.27	18.67	0.7043	260063	5.52956532	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
FBRXForte Biosciences Inc	US$ 13.60 (129.53%)	28.92M
QSIQuantum Si Inc	US$ 1.39 (119.59%)	279.33M
XCURExicure Inc	US$ 11.01 (89.18%)	22.91M
AGFYAgrify Corporation	US$ 37.4635 (68.00%)	921.45k
SLXNSilexion Therapeutics Corporation	US$ 0.3495 (54.51%)	198.66M
SKKSKK Holdings Limited	US$ 4.55 (-47.28%)	816.93k
QMMMQMMM Holdings Limited	US$ 0.713999 (-43.78%)	4.61M
XTKGX3 Holdings Company Ltd	US$ 0.0901 (-37.82%)	5.95M
PRFXPainReform Ltd	US$ 1.02 (-27.14%)	5.09M
GLEGlobal Engine Group Holding Ltd	US$ 3.81 (-26.59%)	230.23k
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.191 (17.39%)	662.68M
DBGIDigital Brands Group Inc	US$ 0.1345 (15.35%)	326.45M
NVDANVIDIA Corporation	US$ 145.89 (-0.76%)	309.57M
QSIQuantum Si Inc	US$ 1.39 (119.59%)	283.09M
SLXNSilexion Therapeutics Corporation	US$ 0.3495 (54.51%)	200.06M